Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition

Patent metadata

Field	Value
Publication number	US-9403899-B2
Application number	US-201213595967-A
Country	US
Kind code	B2
Filing date	Aug 27, 2012
Priority date	Aug 26, 2011
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content.

First claim

What is claimed is:

1. A method for reducing Factor XI (FXI) and/or Factor XIa (FXIa) content in a plasma-derived immunoglobulin composition, the method comprising the steps of:
(a) providing a plasma-derived immunoglobulin composition comprising IgG immunoglobulins and FXI and/or FXIa;
(b) contacting the plasma-derived immunoglobulin composition with a cation exchange resin disposed in a chromatography column under a first solution condition comprising a pH of no more than 6.0 and a conductivity of no more than 11 mS/cm to bind the IgG immunoglobulins and at least a fraction of the FXI and/or FXIa to the cation exchange resin;
(c) eluting the IgG immunoglobulins from the cation exchange resin in a single-step elution by contacting the cation exchange resin with an elution buffer comprising a pH of at least 7.5 and a conductivity of at least 15 mS/cm to form an eluate comprising a leading portion and lagging portion; and
(d) collecting the leading portion of the eluate separately from the lagging portion of the eluate,
wherein the leading portion of the eluate consists of the portion of the eluate having a pH of no more than 6.0, and wherein less than 50% of the FXI and/or FXIa bound to the cation exchange resin in step (b) is present in the leading portion of the eluate collected in step (d).

2. The method of claim 1 , wherein the elution buffer comprises a conductivity of at least 20 mS/cm.

3. The method of claim 1 , wherein the elution buffer comprises a conductivity of at least 25 mS/cm.

4. The method of claim 1 , further comprising a step of washing the cation exchange resin having the immunoglobulins and FXI and/or FXIa bound thereto with a wash buffer comprising a pH of no more than 6.0 and a conductivity of less than 11 mS/cm prior to eluting the immunoglobulins from the cation exchange resin in step (c).

5. The method of claim 1 , wherein the cation exchange resin is a weak cation exchange resin.

6. The method of claim 5 , wherein the weak cation exchange resin is carboxymethyl cation exchange resin.

7. The method of claim 1 , wherein the elution buffer comprises a pH of between 7.5 and 8.5.

8. The method of claim 7 , wherein the elution buffer comprises a pH of 8.0±0.2.

9. The method of claim 1 , wherein the elution buffer comprises between 200 and 300 mM sodium chloride.

10. The method of claim 9 , wherein the elution buffer comprises between 240 and 260 mM sodium chloride.

11. The method of claim 1 , wherein the elution buffer comprises between 100 mM and 300 mM glycine.

12. The method of claim 11 , wherein the elution buffer comprises between 175 mM and 225 mM glycine.

13. The method of claim 1 , wherein the step of collecting the leading portion of the eluate separately from the lagging portion of the eluate comprises collecting eluate having a pH of no more than 6.0 separately from eluate having a pH of more than 6.0.

14. The method of claim 1 , wherein the step of collecting the leading portion of the eluate separately from the lagging portion of the eluate comprises collecting eluate having a pH of no more than 5.5 separately from eluate having a pH of more than 5.5.

15. The method of claim 1 , wherein the step of collecting the leading portion of the eluate separately from the lagging portion of the eluate comprises collecting eluate having a pH of no more than 5.0 separately from eluate having a pH of more than 5.0.

16. The method of claim 1 , wherein the step of collecting the leading portion of the eluate separately from the lagging portion of the eluate comprises monitoring the pH of the eluate.

17. The method of claim 1 , wherein the step of collecting the leading portion of the eluate comprises the sub-steps of:
(i) monitoring the optical density of the eluate at 280 nm (OD 280 );
(ii) beginning collection when the OD 280 of the eluate rises above a first threshold OD 280 of at least 50 mAU; and
(iii) ending collection when the OD 280 of the eluate falls below a second threshold OD 280 of no less than 500 mAU.

18. The method according to claim 17 , wherein the second threshold OD 280 is no less than 1 AU.

19. The method according to claim 17 , wherein the second threshold OD 280 is no less than 2 AU.

20. The method of claim 4 , wherein the wash buffer comprises a pH of between 5.0 and 6.0.

21. The method of claim 20 , wherein the wash buffer comprises a pH of 5.5±0.2.

22. The method of claim 1 , wherein less than 25% of the FXI and/or FXIa bound to the cation exchange resin in step (b) is present in the leading portion of the eluate collected in step (d).

23. The method of claim 1 , wherein less than 10% of the FXI and/or FXIa bound to the cation exchange resin in step (b) is present in the leading portion of the eluate collected in step (d).

24. The method of claim 1 , wherein the amount of FXI and/or FXIa is determined by performing an amidolytic activity assay using a FXIa-specific substrate.

25. The method of claim 1 , wherein the plasma-derived immunoglobulin composition provided in step (a) is a suspended plasma fraction precipitate selected from the group consisting of a Fraction I precipitate, a Fraction I+II+III precipitate, a Fraction II+III precipitate, Fraction IV-1, a Kistler-Nitschmann Precipitate A, a Kistler-Nitschmann Precipitate B, and a modified precipitate thereof.

26. The method of claim 25 , wherein the plasma-derived immunoglobulin composition provided in step (a) is a suspended Fraction II precipitate.

27. The method of claim 1 , wherein the leading portion of the eluate consists of the portion of the eluate having a pH of from 4.0 to 5.0.

28. The method of claim 1 , wherein the leading portion of the eluate consists of the portion of the eluate having a pH of from 4.0 to 5.5.

Assignees

• Teschner Wolfgang
• Butterweck Harald Arno
• Kölbl Bernhard
• Hofbauer Lucia
• Schwarz Hans-Peter
• Baxalta Inc
• Baxalta GmbH

Inventors

• Teschner Wolfgang
• Butterweck Harald Arno
• Kölbl Bernhard
• Hofbauer Lucia
• Schwarz Hans-Peter

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• C07K16/065 Primary

  Purification, fragmentation · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title